Australian Clinical Labs (ASX:ACL) Debt-to-Revenue : 0.48 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Australian Clinical Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$101.8 Mil. Australian Clinical Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$225.3 Mil. Australian Clinical Labs's annualized Revenue for the quarter that ended in Dec. 2023 was A$675.6 Mil. Australian Clinical Labs's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.48.

Australian Clinical Labs Debt-to-Revenue Historical Data

The historical data trend for Australian Clinical Labs's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Debt-to-Revenue Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

Debt-to-Revenue

N/A

0.46

0.27

0.46

Australian Clinical Labs Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial			0.27	0.29	0.44	0.49	0.48

Competitive Comparison of Australian Clinical Labs's Debt-to-Revenue

For the Diagnostics & Research subindustry, Australian Clinical Labs's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Debt-to-Revenue falls into.

Australian Clinical Labs Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Australian Clinical Labs's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(101.085	+	215.234)	/	692.103
	=	0.46

Australian Clinical Labs's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(101.774	+	225.26)	/	675.632
	=	0.48

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Australian Clinical Labs Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs (ASX:ACL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines